Aptar Pharma will commercialize and promote Cambridge Healthcare Innovations’ Quattrii blister-based dry powder inhaler platform, the companies said. According to the announcement, the platform is tunable and can be used with carrier or API-only formulations. CHI’s web site says that the Quattrii DPI can be filled with up to 150 mg of powder and is capable of delivering a greater than 70% fine particle dose for carrier formulations or can clear up to 90% of the fill mass for API-only products.
Aptar notes that the CHI deal contributes to its “leadership in respiratory by offering a broader range of drug delivery formats” among other benefits. In September 2024, Aptar announced that it will promote Pulmotree’s Kolibri mesh nebulizer, including supporting development projects, and the company recently acquired nasal delivery technology from SipNose Nasal Delivery Systems.
CHI CEO David Harris commented, “We are really excited to be partnering with Aptar Pharma to bring our Quattrii DPI platform to market. Through this relationship, Aptar’s pharmaceutical customers will now have access to a next-generation DPI platform capable of delivering high doses of low-potency molecules. This will open up a wide range of opportunities for improved patient outcomes across many new and existing conditions.”
Aptar Pharma VP, Global Pulmonary Category, Howard Burnett, said, “The CHI team brings deep knowledge, experience, and innovation to the dry powder inhaler landscape. Aptar Pharma is very pleased to offer the Quattrii technology in partnership with CHI’s expertise. This enables us to provide full support from our portfolio of services to all drug developers, from formulation development to patient onboarding.”
Read the Aptar Pharma and CHI press release.
